Does evidence support the use of cat allergen immunotherapy?
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Purpose of review: Cat allergy can manifest as allergic rhinitis, conjunctivitis and/or asthma. With widespread cat ownership and exposure, cat allergy has emerged as a major cause of morbidity. Cat allergen immunotherapy is a potential disease modifying treatment for patients with cat allergy. We examine evidence on the effectiveness, cost-effectiveness and safety of cat allergen immunotherapy and consider the clinical contexts in which it should be prescribed. Recent findings: The European Association of Allergy and Clinical Immunology systematic reviews on allergic rhinitis and asthma along with the accompanying guidelines on allergic rhinitis were used as primary sources of evidence. Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are most common routes of administration for allergen immunotherapy (AIT). A limited number of high-quality studies related to cat dander have shown mixed results in improvements in ocular and nasal symptoms, asthma symptoms, peak expiratory flow rate and medication use scores with subcutaneous immunotherapy. Two studies examining cat dander and cat-related allergy response with sublingual immunotherapy have shown mixed results in terms of symptomatic response. One randomized trial examining intralymphatic immunotherapy has shown a positive symptom response and a favourable safety profile. Although studies have reported mixed results regarding safety of SCIT, adverse events have been reported more commonly with SCIT than SLIT. Summary: There is a limited body of high-quality evidence on the effectiveness and safety of cat AIT and no high-quality data on its cost-effectiveness. The available evidence on effectiveness is mixed based on studying a limited array of immunological, physiological and patient-reported outcome measures. Based on this evidence and extrapolating on the wider evidence base in AIT, it is likely that some patients may benefit from this modality of treatment, particularly those with moderate-to-severe disease who are inadequately controlled on allergen avoidance measures and pharmacotherapy and those who are monosensitized to Felix Domesticus 1. Further evidence is, however, required from larger trials before more definitive advice can be offered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: A global synthesis
Mallol, J., Crane, J., von Mutius, E., Odhiambo, J., Keil, U., & Stewart, A. (2013) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2012.03.001 · Cited by 663
Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections
Senti, G., Crameri, R., Kuster, D., Johansen, P., Martinez-Gomez, J. M., Graf, N., Steiner, M., Hothorn, L. A., Grönlund, H., Tivig, C., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.026 · Cited by 271
GA2LEN/EAACI pocket guide for allergen‐specific immunotherapy for allergic rhinitis and asthma
Zuberbier, T., Bachert, C., Bousquet, P. J., Passalacqua, G., Walter Canonica, G., Merk, H., Worm, M., Wahn, U., & Bousquet, J. (2010) · Allergy · doi:10.1111/j.1398-9995.2010.02474.x · Cited by 227
Impact of Allergic Rhinitis Symptoms on Quality of Life in Primary Care
Bousquet, P. J., Demoly, P., Devillier, P., Mesbah, K., & Bousquet, J. (2013) · International Archives of Allergy and Immunology · doi:10.1159/000342991 · Cited by 204
Patel, D., Couroux, P., Hickey, P., Salapatek, A. M., Laidler, P., Larché, M., & Hafner, R. P. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.028 · Cited by 198
Allergic sensitization owing to ‘second-hand’cat exposure in schools
Ritz, B. R., Hoelscher, B., Frye, C., Meyer, I., & Heinrich, J. (2002) · Allergy · doi:10.1034/j.1398-9995.2002.1s3404.x · Cited by 52
Cited by
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Akdis (2020) · doi:10.1111/pai.13189 · Cited by 320
Satyaraj, E., Wedner, H. J., & Bousquet, J. (2019) · Allergy · doi:10.1111/all.14013 · Cited by 78
Evolutionary Biology and Gene Editing of Cat Allergen, Fel d 1
Brackett, N. F., Davis, B. W., Adli, M., Pomés, A., & Chapman, M. D. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0101 · Cited by 31
“4 Despite the prevalence and potential severity of cat allergic disease, current treatments merely address the allergic symptoms (e.g., antihistamines) or have demonstrated inconsistent results (e.g., cat allergen immunotherapy 5,6 ).”
Molecular diagnosis in cat allergy
Popescu, F.-D., Ganea, C. S., Panaitescu, C., & Vieru, M. (2021) · World Journal of Methodology · doi:10.5662/wjm.v11.i3.46 · Cited by 25
Metadata
- Authors
- Dhami, S., & Agarwal, A.
- Venue
- Current Opinion in Allergy & Clinical Immunology
- Published
- 2018-08
- Volume
- 18
- Issue
- 4
- Pages
- 350-355
- ISSN
- 1473-6322 (ISSN-L)
- 1528-4050
- OpenAlex
- W2805341017
- Cited by
- 44
- References
- 6
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Does evidence support the use of cat allergen immunotherapy? https://app.cochat.ai/papers/10.1097/aci.0000000000000457
- The paper
- Dhami, S., & Agarwal, A. (2018). Does evidence support the use of cat allergen immunotherapy? Current Opinion in Allergy & Clinical Immunology. https://doi.org/10.1097/aci.0000000000000457
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.